JS-207

N/A

Report date: 2026/05/20 20:02:01

Base Information

Drug NameJS-207
Drug Alias NameJS-207
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionProgrammed cell death protein 1 blockersVascular endothelial growth factor A inhibitors
TargetsProgrammed cell death protein 1Vascular endothelial growth factor A
Therapy Area/IndicationsSolid tumoursSmall Cell Lung CarcinomaCarcinoma, Non-Small-Cell Lung +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesDotbio Pte LtdShanghai Junshi Biosciences Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShanghai Junshi Biosciences Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursSmall Cell Lung CarcinomaCarcinoma, Non-Small-Cell Lung +[7] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A